{"id":"https://openalex.org/W2908199872","doi":"https://doi.org/10.2478/hkbrd-2018-0009","title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitors\u2013 Rheumatology point of view","display_name":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitors\u2013 Rheumatology point of view","publication_year":2018,"publication_date":"2018-12-01","ids":{"openalex":"https://openalex.org/W2908199872","doi":"https://doi.org/10.2478/hkbrd-2018-0009","mag":"2908199872"},"language":"en","primary_location":{"id":"doi:10.2478/hkbrd-2018-0009","doi":"https://doi.org/10.2478/hkbrd-2018-0009","is_oa":true,"landing_page_url":"https://doi.org/10.2478/hkbrd-2018-0009","pdf_url":null,"source":{"id":"https://openalex.org/S4210173269","display_name":"Hong Kong bulletin on rheumatic diseases","issn_l":"1680-4341","issn":["1680-4341","2415-153X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320322","host_organization_name":"De Gruyter Open","host_organization_lineage":["https://openalex.org/P4310320322","https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter Open","De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hong Kong Bulletin on Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.2478/hkbrd-2018-0009","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024092783","display_name":"Cheuk Man Ho","orcid":"https://orcid.org/0000-0003-1579-7940","observed_orcids":["https://orcid.org/0000-0003-1579-7940"]},"institutions":[{"id":"https://openalex.org/I2800783597","display_name":"Tuen Mun Hospital","ror":"https://ror.org/018nkky79","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I1294586568","https://openalex.org/I2800783597"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Cheuk Man Ho","raw_affiliation_strings":["Tuen Mun Hospital , 23 Tsing Chung Koon Road , Tuen Mun Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tuen Mun Hospital , 23 Tsing Chung Koon Road , Tuen Mun Hong Kong","institution_ids":["https://openalex.org/I2800783597"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033947419","display_name":"Chi Chiu Mok","orcid":"https://orcid.org/0000-0003-3696-1228","observed_orcids":["https://orcid.org/0000-0003-3696-1228"]},"institutions":[{"id":"https://openalex.org/I2800783597","display_name":"Tuen Mun Hospital","ror":"https://ror.org/018nkky79","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I1294586568","https://openalex.org/I2800783597"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Chi Chiu Mok","raw_affiliation_strings":["Department of Medicine, Tuen Mun Hospital , Tuen Mun Hong Kong SAR, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Tuen Mun Hospital , Tuen Mun Hong Kong SAR, China","institution_ids":["https://openalex.org/I2800783597"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2800783597"],"apc_list":null,"apc_paid":null,"fwci":0.1043,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.44923021,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"18","issue":"2","first_page":"56","last_page":"60"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9679999947547913},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":1.0},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.8629999756813049},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/autoimmune-adverse-events","display_name":"autoimmune adverse events","score":0.5419999957084656},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.8180000185966492}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8590127229690552},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7061563730239868},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6441535949707031},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6339486241340637},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6206806898117065},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5026836395263672},{"id":"https://openalex.org/C21705690","wikidata":"https://www.wikidata.org/wiki/Q2907609","display_name":"CTLA-4","level":4,"score":0.4952949583530426},{"id":"https://openalex.org/C169382597","wikidata":"https://www.wikidata.org/wiki/Q21208025","display_name":"Programmed cell death 1","level":5,"score":0.4926636815071106},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4668842852115631},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44991397857666016},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.449530690908432},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.44626516103744507},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4194491505622864},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39303871989250183},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.33014318346977234},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.1838134527206421}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.2478/hkbrd-2018-0009","doi":"https://doi.org/10.2478/hkbrd-2018-0009","is_oa":true,"landing_page_url":"https://doi.org/10.2478/hkbrd-2018-0009","pdf_url":null,"source":{"id":"https://openalex.org/S4210173269","display_name":"Hong Kong bulletin on rheumatic diseases","issn_l":"1680-4341","issn":["1680-4341","2415-153X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320322","host_organization_name":"De Gruyter Open","host_organization_lineage":["https://openalex.org/P4310320322","https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter Open","De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hong Kong Bulletin on Rheumatic Diseases","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:c1f69696aea349fdb264556a6182c6ae","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/c1f69696aea349fdb264556a6182c6ae","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hong Kong Bulletin on Rheumatic Diseases, Vol 18, Iss 2, Pp 56-60 (2018)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.2478/hkbrd-2018-0009","doi":"https://doi.org/10.2478/hkbrd-2018-0009","is_oa":true,"landing_page_url":"https://doi.org/10.2478/hkbrd-2018-0009","pdf_url":null,"source":{"id":"https://openalex.org/S4210173269","display_name":"Hong Kong bulletin on rheumatic diseases","issn_l":"1680-4341","issn":["1680-4341","2415-153X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320322","host_organization_name":"De Gruyter Open","host_organization_lineage":["https://openalex.org/P4310320322","https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter Open","De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hong Kong Bulletin on Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1842042263","https://openalex.org/W2033009850","https://openalex.org/W2097995306","https://openalex.org/W2166662937","https://openalex.org/W2263759961","https://openalex.org/W2265285917","https://openalex.org/W2441690768","https://openalex.org/W2510665785","https://openalex.org/W2565782504","https://openalex.org/W2736166064","https://openalex.org/W2737436316","https://openalex.org/W2747028021","https://openalex.org/W2754782368","https://openalex.org/W2781601010","https://openalex.org/W2789465165"],"related_works":["https://openalex.org/W3196165481","https://openalex.org/W2889741031","https://openalex.org/W3135711106","https://openalex.org/W2952770684","https://openalex.org/W3025099262","https://openalex.org/W3021054555","https://openalex.org/W3045735122","https://openalex.org/W6910155327","https://openalex.org/W6946136392","https://openalex.org/W3084186161"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"development":[2],"of":[3,38,42,60,67],"immunotherapy":[4],"has":[5],"revolutionized":[6],"the":[7,11,39,61,65],"cancer":[8],"treatment":[9,41,73],"in":[10,51,64,69],"recent":[12],"years.":[13],"Immune":[14],"checkpoint":[15],"inhibitors":[16],"(ICPis)":[17],"such":[18],"as":[19],"anti-cytotoxic":[20],"T-lymphocyte-associated":[21],"antigen":[22],"4":[23],"(anti-CTLA-4)":[24],"and":[25,31],"anti-programmed":[26],"cell":[27],"death":[28],"protein":[29],"(anti-PD1)":[30],"its":[32],"ligand":[33],"(anti-PDL1)":[34],"have":[35],"become":[36],"part":[37],"standard":[40],"various":[43],"malignancies.":[44],"Immune-related":[45],"adverse":[46],"events":[47],"(irAEs)":[48],"were":[49],"common":[50],"patients":[52],"treated":[53],"with":[54,74],"ICPis.":[55,75],"Rheumatologists":[56],"should":[57],"be":[58],"aware":[59],"upcoming":[62],"challenges":[63],"management":[66],"irAEs":[68],"a":[70],"patient":[71],"receiving":[72]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-09T07:26:56.047234","created_date":"2019-01-11T00:00:00"}